Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration

Neurobiology of Aging

Volumn 33, Issue 1, 2012, Pages 204.e1-204.e11

  Villar Cheda, Begoña ^a,b   Valenzuela, Rita ^a,b   Rodriguez Perez, Ana I ^a,b   Guerra, Maria J ^a,b   Labandeira Garcia, Jose L ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Aging; Angiotensin; Neuroinflammation; Oxidative stress; Parkinson

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; INTERLEUKIN 1BETA; OXIDOPAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA;

AGED; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC DEGENERATION; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; MALE; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA;

EID: 81355139581     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.08.006     Document Type: Article

References (46)

1. Babior B. NADPH oxidase: An update. Blood 1999, 93:1464-1476.
2. Babior B.M. NADPH oxidase. Curr. Opin. Immunol 2004, 16:42-47.
3. Basso N., Paglia N., Stella I., de Cavanagh E.M., Ferder L., del Rosario L., Arnaiz M., Inserta F. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul. Pept 2005, 128:247-252.
4. Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., Conti S., Rottoli D., Longaretti L., Cassis P., Morigi M., Coffman T.M., Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest 2009, 119:524-530.
5. Bjorklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis 1997, 4:186-200.
6. Cai H., Griendling K.K., Harrison D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci 2003, 24:471-478.
7. Choi D.Y., Zhang J., Bing G. Aging enhances the neuroinflammatory response and alpha-synuclein nitration in rats. Neurobiol. Aging 2010, 31:1649-1653.
8. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., Collier T.J., Carvey P.M. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol. Dis 2007, 26:56-65.
9. Csiszar A., Ungvari Z., Koller A., Edwards J.G., Kaley G. Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries. FASEB J 2003, 17:1183-1185.
10. Deng X.H., Bertini G., Xu Y.Z., Yan Z., Bentivoglio M. Cytokine-induced activation of glial cells in the mouse brain is enhanced at an advanced age. Neuroscience 2006, 141:645-661.
11. Gerhardt G.A., Cass W.A., Yi A., Zhang Z., Gash D.M. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J. Neurochem 2002, 80:168-177.
12. Gildea J.J. Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr. Opin. Nephrol. Hypertens 2009, 18:28-32.
13. Gohlke P., Von Kugelgen S., Jurgensen T., Kox T., Rascher W., Culman J., Unger T. Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats. J. Hypertens 2002, 20:909-918.
14. Gundersen H.J.G., Bendsen T.F., Korbo L., Marcussen N., Moller A., Nielsen K. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988, 96:379-394.
15. Heymes C., Silvestre J.S., Llorens-Cortes C., Chevalier B., Marotte F., Levy B.I., Swynghedauw B., Samuel J.L. Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes. Endocrinology 1998, 139:2579-2587.
16. Ito T., Nishimura Y., Saavedra J. Pre-treatment with candesartan protects from cerebral ischaemia. J. Renin. Angiotensin Aldosterone Syst 2001, 2:174-179.
17. Joglar B., Rodriguez-Pallares J., Rodríguez-Perez A.I., Rey P., Guerra M.J., Labandeira-Garcia J.L. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem 2009, 109:656-669.
18. Jones E.S., Vinh A., McCarthy C.A., Gaspari T.A., Widdop R.E. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol. Ther 2008, 120:292-316.
19. Khan F., Spicarová Z., Zelenin S., Holtbäck U., Scott L., Aperia A. Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells. Am. J. Physiol. Ren. Physiol 2008, 295:F1110-F1116.
20. Koprich J.B., Reske-Nielsen C., Mithal P., Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J. Neuroinflammation 2008, 5:8.
21. Li H., Armando I., Yu P., Escano C., Mueller S.C., Asico L., Pascua A., Lu Q., Wang X., Villar V.A., Jones J.E., Wang Z., Periasamy A., Lau Y.S., Soares-da-Silva P., Creswell K., Guillemette G., Sibley D.R., Eisner G., Gildea J.J., Felder R.A., Jose P.A. Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. J. Clin. Invest 2008, 118:2180-2189.
22. Li J.M., Shah A.M. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J. Biol. Chem 2003, 278:12094-12100.
23. McCormack A.L., Di Monte D.A., Delfani K., Irwin I., DeLanney L.E., Langston W.J., Janson A.M. Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol 2004, 471:387-395.
24. Mertens B., Vanderheyden P., Michotte Y., Sarre S. The role of the central renin-angiotensin system in Parkinson's disease. J. Renin Angiotensin Aldosterone Syst 2010, 11:49-56.
25. Mukai Y., Shimokawa H., Higashi M., Morikawa K., Matoba T., Hiroki J., Kunihiro I., Talukder H.M., Takeshita A. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler. Thromb. Vasc. Biol 2002, 22:1445-1450.
26. Nishimura Y., Ito T., Hoe K., Saavedra J.M. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res 2000, 871:29-38.
27. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., Liu B., Hong J.S. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem 2004, 279:1415-1421.
28. Rey P., Lopez-Real A., Sanchez-Iglesias S., Muñoz A., Soto-Otero R., Labandeira-Garcia J.L. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Agin 2007, 28:555-567.
29. Rodriguez-Pallares J., Parga J.A., Muñoz A., Rey P., Guerra M.J., Labandeira-Garcia J.L. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J. Neurochem 2007, 103:145-156.
30. Rodriguez-Pallares J., Rey P., Parga J.A., Muñoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis 2008, 31:58-73.
31. Rueckschloss U., Quinn M.T., Holtz J., Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol 2002, 22:1845-1851.
32. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunohistochemical study in the rat. Neuroscience 1994, 59:401-415.
33. Seshiah P.N., Weber D.S., Rocic P., Valppu L., Taniyama Y., Griendling K.K. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res 2002, 91:406-413.
34. Sohn H.Y., Raff U., Hoffmann A., Gloe T., Heermeier K., Galle J., Pohl U. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br. J. Pharmacol 2000, 131:667-672.
35. Sugama S., Yang L., Cho B.P., DeGiorgio L.A., Lorenzl S., Albers D.S., Beal M.F., Volpe B.T., Joh T.H. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003, 964:288-294.
36. Suzumura A., Takeuchi H., Zhang G., Kuno R., Mizuno T. Roles of glia-derived cytokines on neuronal degeneration and regeneration. Ann. N Y Acad. Sci 2006, 1088:219-229.
37. Torres E.M., Meldrum A., Kirik D., Dunnett S.B. An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections. J. Neurosci. Methods 2006, 158:64-74.
38. Touyz R.M., Chen X., Tabet F., Yao G., He G., Quinn M.T., Pagano P.J., Schiffrin E.L. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries, regulation by angiotensin II. Circ. Res 2002, 14:1205-1213.
39. Touyz R.M., Endemann D., He G., Li J.S., Schiffrin E.L. Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. Hypertension 1999, 33:366-372.
40. Umemoto S. Angiotensin II type 1 (AT1) receptor deficiency halts the progression of age-related atherosclerosis in hypercholesterolemia: molecular link between the AT1 receptor and hypercholesterolemia. Hypertens. Res 2008, 31:1495-1497.
41. Unger T. Inhibiting angiotensin receptors in the brain: possible therapeutic implications. Curr. Med. Res. Opin 2003, 19:449-451.
42. Ungvari Z., Csiszar A., Kaley G. Vascular inflammation in aging. Herz 2004, 29:733-740.
43. Villar-Cheda B., Sousa-Ribeiro D., Rodriguez-Pallares J., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease. J. Cereb. Blood Flow Metab 2009, 29:230-239.
44. Wu D., Teisman P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A 2003, 100:6145-6150.
45. Wu D., Teisman P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6145-6150.
46. Zeng C., Liu Y., Wang Z., He D., Huang L., Yu P., Zheng S., Jones J.E., Asico L.D., Hopfer U., Eisner G.M., Felder R.A., Jose P.A. Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circ. Res 2006, 99:494-500.